Summary
Previous reports have shown the capacity of diphenylhydantoin (DPH) to attach to the membranes of lymphatic cells as a hapten and thus exert an unspecific influence on their ability to express certain recognition molecules. This led us to the hypothesis, that DPH might as well serve to manipulate the t-helperlymphocytes in a way that the mode of infection of these cells by the HIV might be blocked. In order to verify this hypothesis, we exposed normal control lymphocytes as well as lymphocytes from DPH-treated patients (3×100–150 mg DPH/day, Phenhydan®, for a minimum of 10 days) to radioactively labeled HIV (125I). Remaining radioactivity was assessed using a gamma-counter and measured 64.000–92.000 counts/min (n=24, mean 80.000) for the control lymphocytes, while remaining radioactivity for the DPH-treated lymphocytes ranged between 2000 and 7000 counts/min (n=24, mean 4.000, p<0.001). These results and similar experiments obtained with FITC-labeled HIV led us to the conclusion that DPH inhibits HIV recognition of T-lymphocytes and therefore might be used in therapy and prophylaxis of AIDS.
References
Achour A, Nugeyre MT, Barré-Sinoussi F, Cherman JC (1985) in press. A new approach to Characterize the Susceptible Cells for LAV Infection. Symposium, Kopenhagen
Bluming A, Homer S, Khiroya R (1975) Selective Diphenylhydantoin — induced Supression of Lymphocyte Reactivity in Vivo. J Lab Clin Med 88: 417–422
Coope R, Burrows RGR (1940) Treatment of Epilepsy with Sodium Diphenylhydantoinate. Lancet I: 490
Festoff BW, Appel SH (1968) Effect of Diphenylhydantoin on Synaptosome Sodium-Potassium-ATPase. J Clin Invest 47: 2752–2758
Gleichmann E, Van Elven F, Gleichmann H (1979) Immunoblastic Lymphadenopathy, Systemic Lupus Erythematosus and Related Disorders. Am J Clin Pathol 72: 708–723
Krueger G, Harris D, Sussman E (1972) Effect of Dilantin in mice II. Lymphoreticular Tissue Atypia and Neoplasia after Chronic Exposure. Z Krebsforsch 78: 290–302
Lehr HA, Raisbeck AP (1985) Ungerechtfertigter Ausschluß von Spendernieren nach Phenytoin-Behandlung? Dtsch Med Wochenschr 47: 1834–1835
Lehr HA, Zimmer JP (1986) Diphenylhydantoin in der Therapie und Prophylaxe von AIDS? Dtsch Med Wochenschr 25: 1001–1002
McKinney AA, Booker HE (1972) Diphenylhydantoin Effects on Human Lymphocytes in Vitro and in Vivo. Arch Intern Med 129: 988–992
McKinney AA, Vyas R (1973) The assay of Diphenylhydantoin Effects on Growing Human Lymphocytes. J Pharmacol Exp Ther 186: 37–43
Rausing A (1978) Hydantoin-induced Lymphadenopathies and Lymphomas. Recent Results Cancer Res 64: 263–264
Saltzstein SL, Ackerman LV (1959) Lymphadenopathy Induced by Anticonvulsant Drugs and Mimicking Clinically and Pathologically Malignant Lymphomas. Cancer 12: 164–182
Sorrell TC, Forbes IJ, Burness FR, Rischbieth RHC (1971) Depression of Immunological Function in Patients Treated with Phenytoin Sodium. Lancet II: 1233–1235
Sorrell TC, Forbes IJ (1975) Depression of Immune Competence by Phenytoin and Carbamazepine. Clin Exp Immunol 20: 273–285
Zidar BL, Mendelow H, Winkelstein A, Shadduk RK (1975) Diphenylhydantoin-induced Serum Sickness with Fibrin-Platelet Thrombi in Lymph Node Microvasculature. Am J Med 58: 704–708
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zimmer, J.P., Lehr, H.A., Kornhuber, M.E. et al. Diphenylhydantoin (DPH) blocks HIV-receptor on T-lymphocyte surface. Blut 53, 447–450 (1986). https://doi.org/10.1007/BF00320308
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00320308